Results 101 to 110 of about 55,801 (184)

肿瘤可溶性抗原联合超抗原致敏的DC诱导CIK对鼻咽癌细胞杀伤作用的研究

Zhongguo shiyan zhenduanxue, 2015
目的探讨肿瘤可溶性抗原联合超抗原致敏的树突状细胞（dendritic cells,DCs）诱导细胞因子激活的杀伤细胞（cytokine-induced kill cells,CIK）对鼻咽癌细胞CNE-1的体外杀伤作用。方法分离人外周血单个核细胞（peripheral blood mononuclear cell,PBMC）,采用GM-CSF、IL-4和TNF-α体外诱导培养DC,采用CD3Ab、IFN-γ、IL-2、IL-1等细胞因子诱导培养CIK细胞。鼻咽癌肿瘤可溶性抗原（tumor soluble
李付贵, 陈京, 李晓玲, 方慧云, 季明芳, 程伟民   +5 more
doaj  

Non-Genetically Modified Adoptive Cell Therapies for Solid Tumors: Current Landscape and Future Challenges. [PDF]

Cancer Immunol Immunother
Luo Q, Jiang W, Xie Y, Dai Z, Zhu J, Du Y, Tao X, Lei Z, Chu X, Wang B, Fu G.   +10 more
europepmc   +1 more source

Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial. [PDF]

Cancer Immunol Immunother
Shin H, Park Y, Song BG, Choi WM, Han HJ, Lee Y, Song TJ, Yeon JE, Lim YS, Hur MH, Lee YB, Cho EJ, Yu SJ, Kim YJ, Lee JH, Yoon JH, Lee JH.   +16 more
europepmc   +1 more source

U ZNAKU ZAVIČAJA - U POVODU NAGRADE "FRAN GALOVIĆ" ZDRAVKU SELEŠU [PDF]

, 2015
Mihaela Cik
core   +1 more source

Randomized pilot study of camrelizumab with or without autologous cytokine-induced killer cells in refractory clear cell renal cell carcinoma. [PDF]

Sci Rep
Li S, Qin J, Sun Q, Zhao H, Xiong Y, Wang Y, Han Y, Zhang J, Zhang W, Shen M, Yang F, Ren B, Zhou L, Li R, Hui Z, Tian X, Cao S, Du W, Yu W, Liu L, Zhang X, Ren X.   +21 more
europepmc   +1 more source

Therapeutic Potential of CAR-CIK Cells in Acute Leukemia Relapsed Post Allogeneic Stem Cell Transplantation. [PDF]

Cancers (Basel)
Canichella M, de Fabritiis P, Abruzzese E.   +2 more
europepmc   +1 more source

Synergistic antitumor efficacy of CIK cells combined with PD-1 inhibitors in nasopharyngeal carcinoma. [PDF]

Am J Transl Res
Chen J, Sailihan T, Chen Y, Xv S, Qian J, Shen X, Yang H, Zhang P.   +7 more
europepmc   +1 more source

CIK-augmented anti-PD1/CTLA4 immunotherapy eradicates chemo-resistant ovarian cancer via tripartite mechanistic synergy. [PDF]

Front Oncol
Chen P, Pan J, Chen L, Feng X.
europepmc   +1 more source

Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer. [PDF]

Front Immunol
Zhu Y, Xiong G, Guan M, Sun D, Guo Y, Peng J, Zhu H.   +6 more
europepmc   +1 more source

DEAD-box helicase gcDDX56 disrupts IRF3 nuclear import complex and promotes nuclear IRF3 degradation for enhancing GCRV replication. [PDF]

J Virol
Xiao LL, Chen Y, Zhang J, Xiao J, Feng H, Chang MX.   +5 more
europepmc   +1 more source